ACTH(4-10) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
== Transformation of substrate == Substrate transformation involves the transformation of a specific compound into another, such as in the case of phenylacetylcarbinol, and steroid biotransformation, or the transformation of a raw material into a finished product, in the case of food fermentations and sewage treatment.
The Federal Assembly of Yugoslavia, representing the FR Yugoslavia (1992–2003) was composed of two chambers: the Council of Citizens and the Council of Republics. Whereas the Council of Citizens served as an ordinary assembly, representing the people, the Council of Republics was made equally by representatives from the federation's constituent republics, to ensure federal equality between Serbia and Montenegro. The first president from 1992 to 1993 was Dobrica Ćosić, a former communist Yugoslav partisan during World War II and later one of the fringe contributors of the controversial Memorandum of the Serbian Academy of Sciences and Arts. Despite being head of the country, Ćosić was forced out of office in 1993 due to his opposition to Serbian President Slobodan Milošević. Ćosić was replaced by Zoran Lilić who served from 1993 to 1997, and then followed by Milošević becoming Yugoslav President in 1997 after his last legal term as Serbian president ended in 1997. The FR Yugoslavia was dominated by Milosevic and his allies, until the presidential election in 2000. There were accusations of vote fraud and Yugoslav citizens took to the streets and engaged in riots in Belgrade demanding that Milošević be removed from power. Shortly afterwards Milošević resigned and Vojislav Koštunica took over as Yugoslav president and remained president until the state's reconstitution as the State Union of Serbia and Montenegro.
Paracetamol poisoning, also known as acetaminophen poisoning, is caused by excessive use of the medication paracetamol (acetaminophen). Most people have few or non-specific symptoms in the first 24 hours following overdose. These symptoms include feeling tired, abdominal pain, or nausea. This is typically followed by absence of symptoms for a couple of days, after which yellowish skin, blood clotting problems, and confusion occurs as a result of liver failure. Additional complications may include kidney failure, pancreatitis, low blood sugar, and lactic acidosis. If death does not occur, people tend to recover fully over a couple of weeks. Without treatment, death from toxicity occurs 4 to 18 days later. Paracetamol poisoning can occur accidentally or as a suicide attempt. Risk factors for toxicity include alcoholism, malnutrition, and the taking of certain other hepatotoxic medications. Liver damage results not from paracetamol itself, but from one of its metabolites, N-acetyl-p-benzoquinone imine (NAPQI). NAPQI decreases the liver's glutathione and directly damages cells in the liver. Diagnosis is based on the blood level of paracetamol at specific times after the medication was taken. These values are often plotted on the Rumack-Matthew nomogram to determine level of concern. Treatment may include activated charcoal if the person seeks medical help soon after the overdose. Attempting to force the person to vomit is not recommended. If there is a potential for toxicity, the antidote acetylcysteine is recommended. The medication is generally given for at least 24 hours.
The GABAA receptor agonist gaboxadol (THIP; LU-2-030), a synthetic derivative of the neurotransmitter γ-aminobutyric acid (GABA) and an analogue of the alkaloid muscimol, underwent formal clinical development for the treatment of insomnia and reached phase 3 clinical trials for this indication in the 1990s and 2000s. It was found to effectively improve sleep onset and duration in people with insomnia. In addition, and unlike other hypnotics like benzodiazepines, gaboxadol improved slow wave sleep, preserved sleep architecture, and did not suppress REM sleep. Moreover, in contrast to benzodiazepines, tolerance did not appear to develop to gaboxadol's hypnotic effects. The development of gaboxadol was discontinued in 2007. This was due to high rates of psychiatric and hallucinogenic effects in drug users at supratherapeutic doses, failure of a 3-month efficacy trial, and other cited reasons. Moreover, there was tension concerning hypnotics in the pharmaceutical industry at the time owing to bizarre reports of zolpidem (Ambien)-induced delirium that emerged in the media in 2006, which may have made the developer of gaboxadol more concerned about potential liability issues. According to journalist Hamilton Morris, the discontinuation of gaboxadol's late-stage development may have deprived people with insomnia access to an effective, safe, and non-addictive treatment. There has been some further study of gaboxadol as a hypnotic by David Nutt and colleagues following the discontinuation of its development.
Sources: en.wikipedia.org
=== Street Cricket === The Mid West Rhinos are embarking on another project to bring "Street Cricket" to the suburb of Mbizo. The project which was started by Sporting Chance aims to give young people an opportunity to play a simple version of cricket within their community. Street Cricket can be played with just a bat and ball and it is hoped that by operating this project, the young people will be able to learn new skills and will encourage them to take up the full version of the game. Sponsorship Whilst the funding of local cricket comes from Zimbabwe Cricket, there is still a requirement for sponsorship from external sources. The majority of funding for League cricket comes from the Cold Chain Group. The other sponsors include Lays, Bokomo, Castle and local sponsors such as Steel Makers, Cricket Tours Africa and Vinyl Stikka Signs.
The Yucatec, who came from Yucatán, Mexico, to escape the violent Caste War of the 1840s. The Mopan, who are indigenous to Belize but were forced out to Guatemala by the British for raiding settlements. They returned to Belize to evade enslavement by the Guatemalans in the 19th century. The Q'eqchi', who also fled from slavery in Guatemala in the 19th century. The latter groups are chiefly found in the Toledo District. The Maya speak their native languages and Spanish, and are also often fluent in English and Belizean Creole.
=== Nonspecific pain === Patients with uncomplicated back pain should be encouraged to remain active and to return to normal activities. The management goals when treating back pain are to achieve maximal reduction in pain intensity as rapidly as possible, to restore the individual's ability to function in everyday activities, to help the patient cope with residual pain, to assess for side effects of therapy and to facilitate the patient's passage through the legal and socioeconomic impediments to recovery. For many, the goal is to keep the pain at a manageable level to progress with rehabilitation, which then can lead to long-term pain relief. Also, for some people the goal is to use nonsurgical therapies to manage the pain and avoid major surgery, while for others surgery may represent the quickest path to pain relief. Not all treatments work for all conditions or for all individuals with the same condition, and many must try several treatment options to determine what works best for them. The present stage of the condition (acute or chronic) is also a determining factor in the choice of treatment. Only a minority of people with back pain (most estimates are 1–10%) require surgery.
Gish's debating opponents said that he used a rapid-fire approach during a debate, presenting arguments and changing topics quickly. Eugenie Scott, executive director of the National Center for Science Education, dubbed this approach the "Gish gallop", describing it as "where the creationist is allowed to run on for 45 minutes or an hour, spewing forth torrents of error that the evolutionist hasn't a prayer of refuting in the format of a debate". She also criticized Gish for failing to answer objections raised by his opponents. However, Gish said a similar thing about his debate opponents, especially Kenneth Miller. Gish accused Miller of using spread debating, i.e. speaking very fast and bringing up so many points that there was no chance to answer them all. Gish was also criticized for using a standardized presentation during debates. While undertaking research for a debate with Gish, Michael Shermer noted that Gish re-used similar openings, assumptions about his opponent, slides, and even jokes. For example, during the debate, Gish attempted to prove that Shermer was indeed an atheist and therefore immoral, even though Shermer said he was not an atheist and was willing to accept the existence of a divine creator. Massimo Pigliucci, who debated Gish five times, said that Gish ignored evidence contrary to his religious beliefs. Robert Schadewald accused Gish of stonewalling arguments with fabricated data.
Congenital hereditary endothelial dystrophy (CHED): There are 2 forms of congenital hereditary endothelial dystrophy (CHED). Commonest is an autosomal recessive form, which is present at birth, but nonprogressive. Nystagmus is seen in association with this form. Another is an autosomal dominant form that occurs within the first few years of life. This form is progressive, but nystagmus is not seen. Deafness and CHED are seen in Harboyan syndrome. The histologic findings are very similar to those seen in pseudophakic/ aphakic bullous keratopathy. The appearance of the cornea is similar to that in congenital glaucoma but without increased corneal diameter and elevated intraocular pressure. Posterior polymorphous corneal dystrophy (PPMD, PPCD): PPCD, also known as Schlichting dystrophy, is an autosomal dominant disorder of the corneal endothelium and Descemet's membrane. It is usually present in the second or third decade of life. It has the same entity as the first form of CHED. Most cases of PPMD are asymptomatic, and these cases generally do not require treatment. PPMD patients with bilateral, corneal opacities that can affect vision, descemet's membrane endothelial keratoplasty or penetrating keratoplasty are the treatments of choice to improve vision and to avoid amblyopia. Congenital hereditary stromal dystrophy (CHSD): CHSD is also known as Congenital stromal corneal dystrophy or Congenital stromal dystrophy of the cornea. It is a rare autosomal dominant disease caused by mutations in the DCN gene.
Sources: en.wikipedia.org
Von Willebrand disease (VWD) is a type of blood-clotting disorder. It is the most common hereditary coagulopathy in humans, affecting 1% of the population. An acquired form of VWD can sometimes result from other medical conditions. Most people with VWD have no symptoms. Those that do usually have bleeding of varying intensity, including repeated bruising and nosebleeds. VWD arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a protein required for platelet adhesion through the binding to other proteins, particularly factor VIII. The disease is known to affect several breeds of dogs as well as humans. Four types of hereditary VWD have been described, including platelet-type VWD, with VWD type 1 being the most common. Types 1 and 2 are inherited through an autosomal dominant pattern, meaning at least one parent must also have the disease. Diagnosis is typically confirmed through blood tests. Managing VWD includes the use of desmopressin after minor trauma or before surgery, which allows the body to release more VWF. The disease is named after the Finnish physician Erik Adolf von Willebrand, who first described the condition in 1926.
"Home Tanning of Leather and Small fur Skins" (pub. 1962) hosted by the UNT Government Documents Department Dragoona. "Tanning Leather". Archived from the original on 2024-04-22. Muspratt's mid-19th century technical description of the whole process.
== Biologics, skin substitutes, biomembranes and scaffolds == Advancements in the clinical understanding of wounds and their pathophysiology have commanded significant biomedical innovations in the treatment of acute, chronic, and other types of wounds. Many biologics, skin substitutes, biomembranes and scaffolds have been developed to facilitate wound healing through various mechanisms. This includes a number of products under the trade names such as Epicel, Laserskin, Transcyte, Dermagraft, AlloDerm/Strattice, Biobrane, Integra, Apligraf, OrCel, GraftJacket and PermaDerm.
== Side effects == Very common (incidence > 10%) adverse effects include constipation, dry mouth, and drowsiness at the beginning of treatment. Common (1% < incidence ≤ 10%) adverse effects include drowsiness during maintenance therapy, tremor, headache, dizziness, vertigo, and weakness. Uncommon (0.1% < incidence ≤ 1%) adverse effects include weight gain.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.